Replies to post #384503 on Elite Pharmaceuticals Inc (ELTP)

[mrwrn2010]

I was under the impression that none of the products considered needle movers have been filed yet. I would agree that those two pending approval don’t sound massively impactful. Positive, but not game changing.

I figured Oxy was likely one of the big ones, with a possible Concerta and whatever else.

[The ELTP King]

LMAO!

Those aren't the needle movers.

Those are small products.

the "needle movers" of the Dopamine agonist at $12.4 M filed in December 2022 which should have a PDUFA date around October- November 2023 and the Antimetabolite of $42M with a PDUFA date of March 2024.